Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-25 @ 12:32 AM
Ignite Modification Date:
2025-12-25 @ 12:32 AM
NCT ID:
NCT01767467
Brief Summary:
The purpose of this study is to evaluate the safety and immunogenicity of GSK Biologicals' vaccine GSK1437173A in subjects aged 18 years and older with blood cancers. The study will evaluate safety-related events and antibody and cellular immune responses to the study vaccine, as compared to placebo.
Detailed Description:
Amendment to protocol posting:
Increase in sample size, update of country/region-specific information (Sections 5, 6 and 9).
Promotion of secondary to primary objective; related update of primary and secondary outcome measures (Sections 4 and 7).
Study:
NCT01767467
Study Brief:
Protocol Section:
NCT01767467